Medicines Patent Pool feature story
Long-acting HIV medicines have the potential to transform both treatment and prevention, reducing pill burden, improving adherence, and better reflecting what people living with or at risk of HIV consistently say they want. Yet despite their promise, access to these innovations remains limited, particularly in low- and middle-income countries.
A paper published in February 2026, Accelerating Generic Long-Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access, takes a close look at why that gap persists, and what can be done to close it. The report summarises key discussion points, findings, and outcomes from an international workshop on generic long-acting (LA) antiretrovirals (ARVs) co-organised by the Long-Acting/Extended-Release Antiretroviral Resource Program (LEAP) and the Centre of Excellence for Long-acting Therapeutics (CELT). The workshop brought together regulators, scientists, generic manufacturers, civil society and global health organisations to outline practical pathways to accelerate access to affordable, generic LA ARVs.
Read the full story here.
Source : Medicines Patent Pool
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.